NASDAQ: PTGXProtagonist Therapeutics Inc Stock
$26.85+0.24 (+0.9%)
Updated Apr 23, 2024
PTGX Price
$26.85
Fair Value Price
N/A
Market Cap
$1.56B
52 Week Low
$13.72
52 Week High
$33.34
P/E
-19.32x
P/B
4.65x
P/S
21.69x
PEG
N/A
Dividend Yield
N/A
Revenue
$60.00M
Earnings
-$78.96M
Gross Margin
100%
Operating Margin
-131.59%
Profit Margin
-131.6%
Debt to Equity
0.06
Operating Cash Flow
-$70M
Beta
1.29
Next Earnings
May 2, 2024
Ex-Dividend
N/A
Next Dividend
N/A
PTGX Overview
Protagonist Therapeutics, Inc., a biopharmaceutical company, discovers and develops peptide-based therapeutic drugs to address hematology and blood disorders, and inflammatory and immunomodulatory diseases. It is developing rusfertide (PTG-300), an injectable hepcidin mimetic that is in Phase II clinical trials for the treatment of patients with polycythemia vera and hereditary hemochromatosis, as well as for the treatment of other blood disorders; PN-943, an oral, alpha-4-beta-7 integrin- specific antagonist peptide that is in Phase II clinical trials for treating inflammatory bowel disease (IBD); and PN-235, an orally delivered interleukin-23 receptor specific antagonist for the treatment of IBD and non-IBD indications. The company has a license and collaboration agreement with Janssen Biotech, Inc. Protagonist Therapeutics, Inc. was incorporated in 2006 and is headquartered in Newark, California.
Zen Score
–
Industry Average (23)
You've viewed Zen Score for 10/10 free stocks. Upgrade to Premium to see how PTGX scored across 33 valuation, financial, forecast, performance, and dividend due diligence checks.
Due Diligence Checks
PTGX is unprofitable, so we are unable to calculate its intrinsic value according to an updated version of Benjamin Graham's Formula from "The Intelligent Investor"
Below Benjamin Graham Formula Value Valuation
PTGX is good value based on its book value relative to its share price (4.65x), compared to the US Biotechnology industry average (5.93x)
P/B vs Industry Valuation
PTGX is unprofitable, so we... subscribe to Premium to read more.
PEG Value Valuation
There are 30 more PTGX due diligence checks available for Premium users.
Be the first to know about important PTGX news, forecast changes, insider trades & much more!
PTGX News
Valuation
PTGX fair value
Fair Value of PTGX stock based on Discounted Cash Flow (DCF)
Price
$26.85
Fair Value
-$9.78
Undervalued by
374.55%
PTGX is unprofitable, so we... subscribe to Premium to read more.
Below Benjamin Graham Formula Value Valuation
PTGX price to earnings (PE)
For valuing profitable companies with steady earnings
Company
-19.32x
Industry
16.46x
Market
41.92x
PTGX price to book (PB)
For valuing companies that are loss-making or have lots of physical asset
Company
4.65x
Industry
5.93x
PTGX is good value based... subscribe to Premium to read more.
P/B vs Industry Valuation
PTGX's financial health
Profit margin
Revenue
$60.0M
Net Income
$27.3M
Profit Margin
45.6%
PTGX's cash burn is expected... subscribe to Premium to read more.
Interest Coverage Financials
PTGX's profit margin has increased... subscribe to Premium to read more.
Profit Margin Growth Financials
Assets to liabilities
Assets
$358.0M
Liabilities
$21.3M
Debt to equity
0.06
PTGX's short-term assets ($355.58M) exceed... subscribe to Premium to read more.
Short-term Liabilities Financials
PTGX's short-term assets ($355.58M) exceed... subscribe to Premium to read more.
Long-term Liabilities Financials
PTGX's debt relative to shareholder... subscribe to Premium to read more.
Shrinking Debt Financials
PTGX's debt to equity ratio... subscribe to Premium to read more.
Healthy Debt to Equity Financials
Cash flow
Operating
$17.0M
Investing
-$61.3M
Financing
$527.0k
PTGX's cash and short-term investments... subscribe to Premium to read more.
Debt Coverage Financials
PTGX vs Biotech Stocks
Protagonist Therapeutics Stock FAQ
Company
AboutNewsBlogStock Investing FAQPlansPrivacy PolicyTerms of ServiceCancellation & RefundsHelp GuidesContactTwitterYouTubeNewsletterWallStreetZen does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.
Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.
Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.